Skip to main content
Erschienen in:

01.01.2007 | Leitthema

Angiogenesehemmung in der Onkologie

Neue Substanzen und klinische Anwendung

verfasst von: T. Kessler, R. M. Mesters, Prof. Dr. W. E. Berdel

Erschienen in: Die Onkologie | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zielgerichtete Therapien gewinnen in der Onkologie mehr und mehr an Bedeutung. Insbesondere Inhibitoren der tumorinduzierten Angiogenese sind in den Blickpunkt neuer Therapiestrategien gekommen. Zahlreiche neue Substanzen zur Angiogenesehemmung wurden entwickelt und in klinischen Studien auf Sicherheit, Verträglichkeit und Aktivität überprüft. Einige wenige sind bereits sehr weit in der klinischen Entwicklung und haben durch positive Studienresultate bereits Zulassungsstatus erreicht. Neben dem VEGF-neutralisierenden Antikörper Bevacizumab beim metastasierten kolorektalen Karzinom gilt dies für die Tyrosinkinaseinhibitoren Sorafenib und Sunitinib beim metastasierten Nierenzellkarzinom sowie für Sunitinib zusätzlich beim gastrointestinalen Stromatumor. Das besondere Toxizitätsprofil und die hohen Therapiekosten dieser neuen Substanzen machen eine sorgfältige Patientenselektion mit individueller Nutzen-Risiko-Abwägung erforderlich.
Fußnoten
1
Identifikationsnummern in Klammern beziehen sich auf das Verzeichnis des National Cancer Institute (NCI)
 
Literatur
1.
Zurück zum Zitat Casali PG, Garrett CR, Blackstein ME et al. (2006) Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 9513 Casali PG, Garrett CR, Blackstein ME et al. (2006) Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 9513
2.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345CrossRefPubMed Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345CrossRefPubMed
3.
Zurück zum Zitat Demetri GD, van Oosterom AT, Blackstein M et al. (2005) Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 4000 Demetri GD, van Oosterom AT, Blackstein M et al. (2005) Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 4000
4.
Zurück zum Zitat Eisen T, Bukowski RM, Staehler M et al. (2006) Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 4524 Eisen T, Bukowski RM, Staehler M et al. (2006) Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 4524
5.
Zurück zum Zitat Escudier B, Szczylik C, Eisen T et al. (2005) Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 3 (Issue 2, 13th European Cancer Conference): 794 Escudier B, Szczylik C, Eisen T et al. (2005) Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 3 (Issue 2, 13th European Cancer Conference): 794
6.
Zurück zum Zitat Escudier B, Szczylik C, Eisen T et al. (2005) Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 4510 Escudier B, Szczylik C, Eisen T et al. (2005) Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 4510
7.
Zurück zum Zitat Eskens FA, Dumez H, Hoekstra R et al. (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39: 917–926CrossRef Eskens FA, Dumez H, Hoekstra R et al. (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39: 917–926CrossRef
8.
Zurück zum Zitat Fehrenbacher L, O’Neill V, Belani CP et al. (2006) A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 7062 Fehrenbacher L, O’Neill V, Belani CP et al. (2006) A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 7062
9.
Zurück zum Zitat Gauler TC, Fischer B, Soria J et al. (2006) Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC). J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 7195 Gauler TC, Fischer B, Soria J et al. (2006) Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC). J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 7195
10.
Zurück zum Zitat Giantonio BJ, Catalano PJ, Meropol NJ et al. (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 2 Giantonio BJ, Catalano PJ, Meropol NJ et al. (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 2
11.
Zurück zum Zitat Gutheil JC, Campbell TN, Pierce PR et al. (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6: 3056–3061PubMed Gutheil JC, Campbell TN, Pierce PR et al. (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6: 3056–3061PubMed
12.
Zurück zum Zitat Hecht JR, Trarbach T, Jaeger E et al. (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 3 Hecht JR, Trarbach T, Jaeger E et al. (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 3
13.
Zurück zum Zitat Hersey P, Sosman J, O’Day S et al. (2005) A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 7507 Hersey P, Sosman J, O’Day S et al. (2005) A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 7507
14.
Zurück zum Zitat Hochster HS, Hart LL, Ramanathan RK et al. (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 3510 Hochster HS, Hart LL, Ramanathan RK et al. (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 3510
15.
Zurück zum Zitat Holash J, Davis S, Papadopoulos N et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393–11398CrossRefPubMed Holash J, Davis S, Papadopoulos N et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393–11398CrossRefPubMed
16.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342CrossRefPubMed Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342CrossRefPubMed
17.
Zurück zum Zitat Jayson GC, Mullamitha S, Ton C et al. (2005) Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to av integrins, in patients with solid tumors. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 3113 Jayson GC, Mullamitha S, Ton C et al. (2005) Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to av integrins, in patients with solid tumors. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 3113
18.
Zurück zum Zitat Johnson DH, Fehrenbacher L, Novotny WF et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184–2191 Johnson DH, Fehrenbacher L, Novotny WF et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184–2191
19.
Zurück zum Zitat Koehne C, Bajetta E, Lin E et al. (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 3508 Koehne C, Bajetta E, Lin E et al. (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 3508
20.
Zurück zum Zitat Levine AM, Tulpule A, Quinn DI et al. (2006) Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 24: 1712–1719CrossRefPubMed Levine AM, Tulpule A, Quinn DI et al. (2006) Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 24: 1712–1719CrossRefPubMed
21.
Zurück zum Zitat Mendel DB, Laird AD, Xin X et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327–337PubMed Mendel DB, Laird AD, Xin X et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327–337PubMed
22.
Zurück zum Zitat Miller KD, Wang M, Gralow J et al. (2005) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Research and Treatment 94 (Suppl 1, 28th Annual San Antonio Breast Symposium) Miller KD, Wang M, Gralow J et al. (2005) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Research and Treatment 94 (Suppl 1, 28th Annual San Antonio Breast Symposium)
23.
Zurück zum Zitat Motzer RJ, Hutson TE, Tomczak P et al. (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): LBA3 Motzer RJ, Hutson TE, Tomczak P et al. (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): LBA3
24.
Zurück zum Zitat Motzer RJ, Rini BI, Michaelson MD et al. (2004) SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 (Suppl 14): 4500 Motzer RJ, Rini BI, Michaelson MD et al. (2004) SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 (Suppl 14): 4500
25.
Zurück zum Zitat Mulay M, Limentani SA, Carroll M et al. (2006) Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 13061 Mulay M, Limentani SA, Carroll M et al. (2006) Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 13061
26.
Zurück zum Zitat Posey JA, Ng TC, Yang B et al. (2003) A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9: 1323–1332PubMed Posey JA, Ng TC, Yang B et al. (2003) A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9: 1323–1332PubMed
27.
Zurück zum Zitat Ratain MJ, Eisen T, Stadler WM et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505–2512 Ratain MJ, Eisen T, Stadler WM et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505–2512
28.
Zurück zum Zitat Rixe O, Verslype C, Méric JB et al. (2006) Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 13161 Rixe O, Verslype C, Méric JB et al. (2006) Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol ASCO Annual Meeting Proceedings 24 (Suppl 18): 13161
29.
Zurück zum Zitat Saltz LB, Lenz H, Kindler H et al. (Eds) (2005) Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. In: Gastrointestinal Cancers Symposium. Orlando, Florida Saltz LB, Lenz H, Kindler H et al. (Eds) (2005) Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. In: Gastrointestinal Cancers Symposium. Orlando, Florida
30.
Zurück zum Zitat Sandler AB, Gray R, Brahmer J et al. (2005) Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial – E4599. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 4 Sandler AB, Gray R, Brahmer J et al. (2005) Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial – E4599. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 4
31.
Zurück zum Zitat Sun Y, Wang J, Liu J et al. (2005) Results of Phase III trial of EndostarTM (rh-endostatin, YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 7138 Sun Y, Wang J, Liu J et al. (2005) Results of Phase III trial of EndostarTM (rh-endostatin, YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol ASCO Annual Meeting Proceedings 23 (Suppl 16): 7138
32.
Zurück zum Zitat Thomas AL, Morgan B, Drevs J et al. (2003) Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 30: 32–38 Thomas AL, Morgan B, Drevs J et al. (2003) Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 30: 32–38
33.
Zurück zum Zitat Willett CG, Boucher Y, di Tomaso E et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145–147CrossRefPubMed Willett CG, Boucher Y, di Tomaso E et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145–147CrossRefPubMed
34.
Zurück zum Zitat Wood JM, Bold G, Buchdunger E et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178–2189PubMed Wood JM, Bold G, Buchdunger E et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178–2189PubMed
35.
Zurück zum Zitat Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434CrossRef Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434CrossRef
Metadaten
Titel
Angiogenesehemmung in der Onkologie
Neue Substanzen und klinische Anwendung
verfasst von
T. Kessler
R. M. Mesters
Prof. Dr. W. E. Berdel
Publikationsdatum
01.01.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 1/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1156-x

Weitere Artikel der Ausgabe 1/2007

Der Onkologe 1/2007 Zur Ausgabe

Neu im Fachgebiet Onkologie

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Warum junge Brustkrebspatientinnen die endokrine Therapie absetzen

15.07.2024 Mammakarzinom Nachrichten

Bei jungen Brustkrebspatientinnen ist die Wahrscheinlichkeit groß, dass sie eine adjuvante endokrine Therapie vorzeitig absetzen. In einer europäischen Kohorte wurden dafür zwei Risikofaktoren identifiziert, die bei der Behandlung berücksichtigt werden sollten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.